MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

$FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma$

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog®

ImmunityBio Announces FDA Approval of ANKTIVA®,

22 Apr 2024

ImmunityBio, Inc. an immunotherapy company, today announced that the U.S. Food and Drug...

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

HanAll Biopharma releases Q3 2024 financial results and shares business updates

$ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.$

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

By Niagen Bioscience, Inc
Niagen Bioscience, Inc
01 Oct 2025

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

By Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation
01 Oct 2025

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

By CollPlant
CollPlant
30 Sep 2025

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

By Corstasis Therapeutics Inc.
Corstasis Therapeutics Inc.
29 Sep 2025

Leqembi® has received approval for intravenous maintenance treatment in China

By BioArctic AB
BioArctic AB
29 Sep 2025

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

By Bayer
Bayer
25 Sep 2025

Pharmaceutical

2nd International Conference on Stem Cells and Regenerative Medicine 2025

10 Nov 2025 10:00 am - 11 Nov 2025 5:30 pm

USA
Pharmaceutical

2nd International Conference on Immunology & Vaccination 2025

10 Nov 2025 10:00 am - 12 Nov 2025 5:30 pm

Paris

Most Popular

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

By AdvanCell

Apr 14
MTF Biologics and Centurion Therapeutics Partner to Expand Access to Advanced Wound Care Technologies

By MTF Biologics

Jun 13
CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

By CollPlant

Aug 20

October 2025

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Search your requirement

Social media

MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season

OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

ProJenX announces the formation of its Clinical Advisory Board

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic

FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog®

ImmunityBio Announces FDA Approval of ANKTIVA®,

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

BioCare collaborates with AeroSafe Global to introduce sustainable cold chain solutions

HanAll Biopharma releases Q3 2024 financial results and shares business updates

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Leqembi® has received approval for intravenous maintenance treatment in China

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

Most Popular

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

MTF Biologics and Centurion Therapeutics Partner to Expand Access to Advanced Wound Care Technologies

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

User Area

Discover

Engage with Us

Search your requirement

Social media

Featured Press Releases

Most Popular

User Area

Discover

Engage with Us

Subscribe for e-Newsletter Monthly